-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Grace Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2018 to Q3 2025.
- Grace Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $0.000.
- Grace Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was -$1.62M, a 39.3% increase year-over-year.
- Grace Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was -$3.2M, a 74.6% decline from 2023.
- Grace Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$1.83M, a 80.8% increase from 2022.
- Grace Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$9.54M, a 1373% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)